Term
|
Definition
• Muscarinic • Hypotonic neurogenic Bladder • Urinary retention • Intestinal atony |
|
|
Term
|
Definition
• Mainly cardivascular Muscarinic • Brachial airway hyperreactivity • Asthma |
|
|
Term
|
Definition
• Autonomic ganglia, presynaptic nerve terminals, and central nervous system • Increased IP3 • Modulation of neurotransmission |
|
|
Term
|
Definition
• Cardiac tissue (sinoatrial and atrioventricular nodes) • Increased potassium efflux or decreased cAMP • Slowing of heart rate and conduction |
|
|
Term
|
Definition
• Smooth muscle and glands • Increased IP3 • Contraction of smooth muscles and stimulation of glandular secretions • Vascular smooth muscle • Increased cGMP due to nitric oxide stimulation • Vasodilation |
|
|
Term
|
Definition
• Neuromuscular junctions • Increased sodium influx • Muscle contraction |
|
|
Term
Nicotinic Ganglionic type |
|
Definition
• Autonomic ganglia • Increased sodium influx • Neuronal excitation |
|
|
Term
|
Definition
• Central nervous system • Increased sodium influx • Neuronal excitation |
|
|
Term
|
Definition
|
|
Term
Dopaminergic/-adrenergic/ M2 receptors |
|
Definition
|
|
Term
|
Definition
|
|
Term
Peptide transmitters R (angiotensin, substance P) |
|
Definition
|
|
Term
Direct Acting CHOLINERGIC AGONIST |
|
Definition
Achetylcholine Bethanechol Methacoline Pilocarpine Succinylcholine Nicotine |
|
|
Term
Indirect Acting (reversible) CHOLINERGIC AGONIST |
|
Definition
Edrophonium Neostigmine Physostigmine Pyridostigmine |
|
|
Term
Indirect Acting (irreversible) CHOLINERGIC AGONIST |
|
Definition
Echothiophate Isoflurophate |
|
|
Term
Reactivation of Acetylcholine Esterase CHOLINERGIC AGONIST |
|
Definition
|
|
Term
Muscarinic Receptor Agonists |
|
Definition
o Clinically used for diagnosis of asthma and miotics o Structure variation: amphipathic vs. charged |
|
|
Term
Pilocarpine Tretiary amine |
|
Definition
• Muscarinic • Glaucoma • Miosis induction • Xerostomia or xerophalmia |
|
|
Term
pharmacology of the cholinomimetics |
|
Definition
o The major therapeutic uses: Glaucoma (closed angle and wide angle) • Glaucoma is a disease characterized by increased intraocular pressure. Mechanism: Muscarinic stimulants and cholinesterase inhibitors reduce intraocular pressure by causing contraction of the ciliary body so as to facilitate outflow of aqueous humor/diminishing the rate of its secretion. Treatment: direct agonists (pilocarpine, emergency treatment ) or cholinesterase inhibitors (echothiophate, isoflurophate longer duration of action). For chronic glaucoma, these drugs have been largely replaced by topical -blockers and prostaglandin derivatives. |
|
|
Term
|
Definition
2 agonist) dilate bronchioles selectively |
|
|
Term
|
Definition
(1 antagonist) selectively decrease heart rate |
|
|
Term
|
Definition
Pharmacological M-agonist bethanecol (GI and urinary tract motility) |
|
|
Term
|
Definition
M-antagonist atropine (dilate pupils- mydriais/ increase heart rate) action |
|
|
Term
|
Definition
Neuronal- excites neurotransmission
NN: a and b subunits |
|
|
Term
|
Definition
–somatic neuromuscular – excites muscle contraction
NM:5 subunits; 30-50% homology |
|
|
Term
|
Definition
selectively blocks α-adrenoceptors |
|
|
Term
|
Definition
selective β-adrenoceptors blocker |
|
|
Term
Inhibit synthesis of neurotransmitter |
|
Definition
• Hemicholinium • Metyrosine (alpha-methyl-para-tyrosine) |
|
|
Term
Prevent vesicular storage of neurotransmitter |
|
Definition
|
|
Term
Inhibit release of neurotransmitter |
|
Definition
• Botulinum toxin • Bretylium |
|
|
Term
Increase release of neurotransmitter |
|
Definition
• Black widow spider venom (α-latrotoxin)* • Amphetamine |
|
|
Term
Inhibit reuptake of neurotransmitter |
|
Definition
|
|
Term
Inhibit metabolism of neurotransmitter |
|
Definition
• Cholinesterase inhibitors (physostigmine) • Monoamine oxidase inhibitors (phenelzine) |
|
|
Term
Activate postsynaptic receptors |
|
Definition
• Acetylcholine, bethanechol, and pilocarpine • Albuterol, dobutamine, and epinephrine |
|
|
Term
Block postsynaptic receptors |
|
Definition
• Atropine and tubocurarine (block muscarinic and nicotinic receptors, respectively) • Phentolamine and propranolol (block α- and β-adrenoceptors, respectively) |
|
|
Term
|
Definition
• mediate smooth muscle and glands contraction |
|
|
Term
|
Definition
• cause transmitter release, contraction |
|
|
Term
Activation of β1-adrenoceptors |
|
Definition
• produces cardiac stimulation |
|
|
Term
|
Definition
• mediate smooth muscle relaxation |
|
|